- Molecular NameHydroxyurea
- SynonymCarbamohydroxamic Acid; Carbamohydroximic Acid; Carbamohydroxyamic Acid; Carbamoyl Oxime; Carbamyl Hydroxamate; HU; Hydroxicarbamidum; Hydroxycarbamide; Hydroxycarbamine; Hydroxylurea; Idrossicarbamide [Dcit]; N-Carbamoylhydroxylamine; N-Hydroxyurea; Sterile Urea
- Weight76.055
- Drugbank_IDDB01005
- ACS_NO127-07-1
- Show 2D model
- LogP (experiment)-1.8
- LogP (predicted, AB/LogP v2.0)-1.66
- pka10.6
- LogD (pH=7, predicted)-1.66
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)1.11
- LogSw (predicted, AB/LogsW2.0)113.16
- Sw (mg/ml) (predicted, ACD/Labs)981.14
- No.of HBond Donors4
- No.of HBond Acceptors4
- No.of Rotatable Bonds0
- TPSA75.35
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antineoplastic drug used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocytosis. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.
- Absorption_valueN/A
- Absorption (description)Well absorbed from the gastrointestinal tract.
- Caco_2N/A
- Bioavailability79.0
- Protein binding0.0
- Volume of distribution (VD)19.7 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmLiver
- Half life3.4 h
- ExcretionRenal and lungs
- Urinary Excretion35.8
- Clerance72 ml/min/m2
- ToxicityTeratogenic effects have occurred in experimental animals.Hydroxyurea use during a small number of human pregnancies has been reported. Adverse effects have not been observed in any of the exposed newborns. Reproductive Effects: Adverse reproductive effects have occurred in experimental animals. Mutagenicity: Mutagenic effects have occurred in experimental animals.Mutagenic effects have occurred in humans.
- LD50 (rat)LD50=5760 mg/kg
- LD50 (mouse)LD50 = 7330 mg/kg